Medigen and the University of Louisville (UofL) present collaborative research on V5040 chikungunya vaccine at the Annual meeting of the American Society for Virology in Columbus, OH. Scientists showed that novel vaccine developed by Medigen and UofL is safe, highly immunogenic, and protects C56BL/6J mice from experimental challenge with infectious chikungunya virus. Chikungunya virus is a life-threatening disease transmitted to people by mosquito bites. Vaccine was developed using Medigen’s patented vaccine technology. Additional evaluation of V5040 vaccine is warranted before human clinical trials.